List of Excipients in Branded Drug HYDROCORTISONE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Mylan Pharmaceuticals Inc	HYDROCORTISONE	hydrocortisone	59762-0073	CALCIUM STEARATE
Mylan Pharmaceuticals Inc	HYDROCORTISONE	hydrocortisone	59762-0073	LACTOSE
Mylan Pharmaceuticals Inc	HYDROCORTISONE	hydrocortisone	59762-0073	MINERAL OIL

Generic Drugs Containing HYDROCORTISONE

Company	Ingredient	NDC	Excipient
Amneal Pharmaceuticals of New York LLC	hydrocortisone	0115-1696	CELLULOSE, MICROCRYSTALLINE
Amneal Pharmaceuticals of New York LLC	hydrocortisone	0115-1696	CROSCARMELLOSE SODIUM
Amneal Pharmaceuticals of New York LLC	hydrocortisone	0115-1696	LACTOSE

What are the Most Frequently-Used Excipients in HYDROCORTISONE?

# Of NDCs	Excipient
1	ALCOHOL
4	ANHYDROUS CITRIC ACID
2	ANHYDROUS LACTOSE

Hydrocortisone Excipient Strategy and Commercial Opportunities

Last updated: August 25, 2026

Hydrocortisone is a mature corticosteroid with limited molecule-level exclusivity but continuing commercial opportunities in pediatric replacement therapy, modified-release products, preservative-free injections, dermatology, rectal delivery, ophthalmic formulations, and differentiated excipient systems. The strongest opportunities are formulation-led: improving dose flexibility, stability, tolerability, administration convenience, and adherence rather than seeking protection for hydrocortisone itself.

What is the commercial opportunity for hydrocortisone excipient innovation?

Hydrocortisone is available in oral tablets, oral granules, injectable preparations, creams, ointments, lotions, foams, suppositories, enemas, and ophthalmic products. The active ingredient is inexpensive and widely manufactured, so commercial value depends on product differentiation.

Opportunity area	Primary formulation problem	Excipient-led solution	Commercial value
Pediatric adrenal insufficiency	Small doses, swallowing difficulty, dose manipulation	Taste masking, multiparticulates, sprinkle granules, dose-scalable sachets	High
Circadian hormone replacement	Short half-life and nonphysiologic exposure from immediate-release tablets	Modified-release matrix or multiparticulate system	High
Injectable hydrocortisone	Reconstitution, oxidation, preservative intolerance	Lyophilized cake, antioxidant control, preservative-free presentation	Medium to high
Topical dermatology	Irritation, poor spreadability, limited residence time	Emulsion, gel, foam, occlusive or film-forming systems	Medium
Rectal therapy	Leakage and poor retention	Mucoadhesive gels, foams, suppository bases	Medium
Ophthalmic therapy	Sterility, comfort, suspension uniformity	Preservative-free multidose systems, particle-size control	Medium
OTC skin products	Commodity pricing and intense competition	Sensory improvement, barrier-support excipients, packaging differentiation	Low to medium

The most defensible commercial positions are products that solve a measurable clinical problem. A new cream with conventional excipients has limited pricing power. A pediatric granule or modified-release product with demonstrated pharmacokinetic or adherence benefits has stronger market access potential.

Which hydrocortisone dosage forms have the greatest excipient potential?

Oral tablets and pediatric granules

Immediate-release tablets are mature products with broad generic competition. Excipient innovation is most valuable where patients need doses below available tablet strengths or cannot swallow tablets.

A pediatric oral granule strategy can use:

• Microcrystalline cellulose or mannitol as a carrier.
• Sucrose, xylitol, maltitol, or other sweetening systems for palatability.
• Flavors selected for low-volume administration.
• Colloidal silicon dioxide to improve powder flow.
• Crospovidone, croscarmellose sodium, or sodium starch glycolate where rapid dispersion is required.
• Film-coating polymers to reduce dusting and improve handling.
• Packaging that supports unit-dose administration and minimizes dosing errors.

Hydrocortisone is used in children with congenital adrenal hyperplasia and other causes of adrenal insufficiency. The formulation must support accurate low-dose delivery, simple administration with soft food or liquid, and acceptable taste. The FDA-approved Alkindi Sprinkle product illustrates the commercial value of pediatric granule technology for hydrocortisone replacement therapy.[1]

The primary development risks are dose uniformity, segregation during filling, moisture sensitivity, powder adhesion to food or containers, and loss of dose after administration. Excipient selection must be evaluated against pediatric safety standards, including age-related exposure limits and the FDA Inactive Ingredient Database.[2]

Modified-release oral formulations

Hydrocortisone has a short biological half-life. Conventional tablets produce rapid exposure and do not reproduce the normal early-morning cortisol rise. Modified-release products seek to improve pharmacokinetic coverage and reduce dosing frequency.

Potential systems include:

• Hydrophilic matrix tablets using hypromellose.
• Multiparticulates with pH-dependent or time-dependent coatings.
• Osmotic systems.
• Layered tablets with immediate-release and delayed-release fractions.
• Capsule-in-capsule systems.
• Coated granules with targeted gastric or intestinal release.

Modified-release development must control dose dumping, food effects, alcohol effects, and interpatient variability. The excipient system is often the principal source of product differentiation and patentable subject matter.

Commercially, the value proposition is strongest for patients who require multiple daily doses or experience poor disease control under immediate-release therapy. Efmody, marketed in Europe for adrenal insufficiency, demonstrates the commercial pathway for modified-release hydrocortisone capsules.[3]

Injectable hydrocortisone

Hydrocortisone injection products generally use hydrocortisone sodium succinate, a water-soluble ester, rather than unmodified hydrocortisone. The ester is the active pharmaceutical ingredient in those products and should not be treated as an excipient choice.

Excipient and presentation priorities include:

• Rapid reconstitution.
• Low particulate burden.
• Controlled pH and osmolality.
• Protection from oxidation and degradation.
• Preservative-free single-dose formats.
• Compatibility with intravenous and intramuscular administration.
• Stable lyophilized cake structure.
• Low extractables and leachables from the container closure system.

Common formulation components can include phosphate buffers, sodium hydroxide or hydrochloric acid for pH adjustment, and bulking agents for lyophilization. Preservatives such as benzyl alcohol or parabens require careful assessment, particularly for neonates, infants, and critically ill patients. The specific excipient profile must follow the approved product label and route-specific safety requirements.[4]

A commercial opportunity exists in ready-to-use or premixed presentations that reduce preparation time in emergency departments and hospitals. The business case depends on reducing medication-preparation errors, wastage, and nursing labor rather than on API cost.

What excipients are suitable for topical hydrocortisone products?

Topical hydrocortisone is a crowded market. Product differentiation depends on vehicle performance, cosmetic acceptability, irritation profile, and treatment-site suitability.

Creams and lotions

Oil-in-water emulsions can improve spreadability and washability. Typical excipient categories include:

• Emulsifiers and co-emulsifiers.
• Humectants such as glycerin or propylene glycol.
• Emollients and occlusives.
• Carbomer or cellulose-based viscosity modifiers.
• Chelating agents such as disodium edetate.
• Preservatives appropriate for the water activity and packaging system.

Anhydrous ointments generally provide greater occlusion and may be useful for dry or lichenified lesions. Petrolatum, mineral oil, paraffin, and wax systems are established choices, but they offer limited intellectual-property differentiation unless combined with improved delivery, sensory performance, or packaging.

Foams and gels

Foams can improve application to the scalp and intertriginous areas. Gels may provide rapid drying and reduced greasiness. Their development risks include:

• Solvent irritation.
• Flammability for hydroalcoholic systems.
• Polymer incompatibility.
• Phase separation.
• Drug crystallization during storage.
• Packaging and actuator compatibility.

Film-forming polymers may increase residence time but can also produce tackiness, peeling, or patient dissatisfaction. A commercial claim based on enhanced residence time requires comparative clinical or pharmacodynamic support.

Preservative strategy

Preservative-free multidose topical products can command a premium where chronic use, sensitive skin, or preservative intolerance is relevant. Airless pumps, metered-dose containers, and unit-dose packaging can reduce microbial risk without relying on conventional preservative systems.

The trade-off is higher packaging cost, more complex microbial challenge testing, and greater dependence on container-closure performance. The formulation must comply with applicable USP microbial and preservative-effectiveness requirements.[5]

What excipient strategy is appropriate for rectal and ophthalmic hydrocortisone?

Rectal formulations

Rectal hydrocortisone products include suppositories, creams, foams, and enemas. The principal technical problems are retention, distribution, leakage, and local tolerability.

Useful excipient approaches include:

• Fatty suppository bases for controlled melting.
• Polyethylene glycol bases for higher melting points and reduced leakage.
• Mucoadhesive polymers such as carbomers or polycarbophil.
• Foam systems that expand within the rectum and improve coverage.
• Isotonic aqueous vehicles for enemas.
• Low-irritancy surfactant systems.

A mucoadhesive or low-volume product may support differentiation, but the clinical benefit must be demonstrated through retention, symptom control, or reduced dosing frequency.

Ophthalmic formulations

Ophthalmic hydrocortisone products require sterility, acceptable osmolality, controlled pH, low particulate content, and good ocular comfort. Suspension products require particle-size control and redispersibility. Potential excipient categories include:

• Isotonicity agents.
• Buffers.
• Suspending agents.
• Wetting agents.
• Viscosity enhancers.
• Chelators.
• Preservatives or preservative-free delivery systems.

Preservative-free packaging is a credible commercial opportunity for repeated ocular dosing, particularly where ocular-surface disease or chronic exposure is a concern. Device performance becomes part of the product’s competitive position, and the combination of formulation, container, and dosing mechanism may create stronger protection than the composition alone.

How can hydrocortisone excipients support patent protection?

Hydrocortisone has no commercially meaningful new chemical entity exclusivity. Patent value therefore usually comes from formulation, use, device, process, or combination claims.

Patentable formulation elements

Potential claim categories include:

• Specific hydrocortisone particle-size distributions.
• Defined excipient ratios.
• Modified-release coating structures.
• Pediatric granule compositions.
• Taste-masking systems.
• Moisture-control packaging.
• Preservative-free multidose delivery.
• Stable lyophilized injectable compositions.
• Mucoadhesive rectal systems.
• Topical vehicles with specified rheology or permeation characteristics.
• Manufacturing processes that reduce degradation or improve content uniformity.

A patent application must establish a technical effect. Generic claims covering hydrocortisone plus commonly used excipients face substantial novelty, obviousness, written-description, and enablement risks. Stronger claims link the excipient system to measured results such as improved stability, reduced variability, controlled release, improved palatability, reduced irritation, or enhanced dose recovery.

Regulatory exclusivity and Orange Book relevance

The Orange Book identifies FDA-approved prescription drug products and certain patent and exclusivity information. Mature hydrocortisone products generally have limited remaining regulatory exclusivity, while newer dosage forms may receive product-specific periods of exclusivity or pediatric exclusivity depending on the approval pathway.[6]

Protection type	Relevance to hydrocortisone
New chemical entity exclusivity	Generally unavailable for mature hydrocortisone products
New clinical investigation exclusivity	Possible for qualifying new formulations or uses
Pediatric exclusivity	Possible if FDA requirements are met
Orphan-drug exclusivity	Possible for qualifying rare-disease indications
Formulation patents	Primary protection route
Method-of-use patents	Relevant to circadian dosing, pediatric replacement, or specific disease populations
Device patents	Relevant to pumps, dispensers, and unit-dose systems
Process patents	Relevant where manufacturing creates a measurable product advantage

Patent-term calculations are product-specific. A reliable expiration date requires review of the relevant patent, patent-term adjustment, terminal disclaimers, regulatory patent extensions, and litigation history. A molecule-wide hydrocortisone expiration date is not an accurate commercial metric.

When does hydrocortisone lose exclusivity and what generic entry risks exist?

For conventional hydrocortisone tablets, creams, ointments, and many injectable products, generic and multisource competition is already established. Generic entry risk is therefore highest for undifferentiated products with:

• Conventional excipients.
• Simple immediate-release dosage forms.
• Standard topical vehicles.
• No meaningful device dependency.
• No listed formulation or method-of-use patent barrier.
• Low switching costs for pharmacies and hospitals.

Risk is lower for products requiring complex formulation development, specialized manufacturing, or device-specific administration. Modified-release capsules, pediatric multiparticulates, sterile lyophilized products, and proprietary topical delivery systems can create greater technical barriers.

Paragraph IV challenges may arise against listed patents covering a branded formulation or use. The relevant assessment requires review of FDA Orange Book patent listings, ANDA certifications, complaint filings, court docket activity, and any settlement agreement. Hydrocortisone’s age does not eliminate litigation risk because newer formulation patents can remain enforceable long after the API itself became generic.

What is the biosimilar risk for hydrocortisone?

Hydrocortisone is a small-molecule corticosteroid, not a biologic. Biosimilar competition does not apply. Competition occurs through generic drug applications, abbreviated new drug applications, hybrid applications outside the United States, OTC monograph products, and authorized-generic arrangements.

The principal competitive threats are:

• Low-cost immediate-release tablets.
• Store-brand topical products.
• Hospital-contract injectable products.
• Compounded pediatric preparations.
• Newer modified-release hydrocortisone products.
• Digital adherence and dose-management services linked to replacement therapy.

Which companies and product types compete in hydrocortisone?

Competition is fragmented by route and market.

Segment	Representative product types	Competitive basis
Oral immediate release	Hydrocortisone tablets and branded tablets	Price, tablet strengths, supply reliability
Pediatric oral	Hydrocortisone granules or compounded liquids	Dose accuracy, palatability, administration
Modified release	Delayed- or sustained-release capsules	Circadian exposure and adherence
Injection	Hydrocortisone sodium succinate vials and premixes	Reconstitution speed, stability, hospital pricing
Dermatology	OTC and prescription creams, ointments, lotions	Vehicle, sensory profile, retail distribution
Rectal	Suppositories, foams, enemas, creams	Coverage, retention, symptom relief
Ophthalmic	Suspensions and specialty products	Sterility, comfort, particle control

For investors and licensors, the most attractive targets are products with differentiated delivery and a defined prescriber or payer rationale. A conventional hydrocortisone cream is unlikely to sustain a premium absent a strong brand, channel advantage, or consumer-perceived benefit.

How should manufacturers design an excipient development program?

A commercially relevant development program should begin with the target product profile rather than an available excipient catalog.

Recommended development sequence

1. Define the route, patient population, dose range, dosing frequency, and administration environment.
2. Identify the dominant failure mode: taste, dose accuracy, instability, irritation, leakage, reconstitution, or exposure variability.
3. Screen excipients using regulatory history, route-specific safety, supply continuity, and manufacturing compatibility.
4. Establish critical material attributes, including particle size, moisture, viscosity, grade, and peroxide content.
5. Use design-of-experiments studies to separate excipient effects from process effects.
6. Generate comparative data against the leading reference product.
7. Align the formulation with the intended regulatory pathway and patent strategy.
8. Lock the supplier and grade early for high-risk excipients.
9. Validate container-closure, extractables, leachables, microbial control, and transport stability.
10. Build freedom-to-operate analysis around formulation, process, device, and use claims.

Excipient suppliers with strong pharmaceutical-grade documentation, global manufacturing redundancy, and established regulatory packages can reduce approval risk. Novel excipients may create differentiation but introduce greater regulatory uncertainty and development cost.

What licensing opportunities exist for hydrocortisone formulations?

Licensing opportunities are most credible in four areas:

• Pediatric multiparticulate delivery.
• Modified-release circadian replacement.
• Preservative-free injectable or ophthalmic systems.
• Topical or rectal delivery platforms that can be applied to other corticosteroids.

A platform license may be more valuable than a hydrocortisone-only deal if the technology also supports prednisone, prednisolone, dexamethasone, or other poorly soluble or short-half-life drugs. Commercial diligence should test whether the excipient system provides a reproducible benefit across active ingredients or depends on hydrocortisone-specific chemistry.

Royalty expectations will depend on patent term, regulatory status, clinical differentiation, manufacturing complexity, and the size of the target population. Pediatric adrenal insufficiency products may have smaller volumes but stronger unmet-need positioning. OTC dermatology products have larger unit volumes but lower margins and greater retailer pressure.

Key Takeaways

• Hydrocortisone is a mature small-molecule drug with limited molecule-level exclusivity.
• The strongest commercial opportunities are pediatric granules, modified-release replacement therapy, preservative-free injectables, and differentiated local-delivery systems.
• Excipient selection should target a specific clinical or operational problem.
• Formulation patents are more relevant than composition-of-matter patents.
• Generic competition is entrenched for conventional tablets and topical products.
• Biosimilar risk does not apply because hydrocortisone is not a biologic.
• Pediatric safety, preservative exposure, stability, dose uniformity, and container compatibility are central development issues.
• The most valuable licensing assets are formulation platforms with evidence of improved pharmacokinetics, adherence, tolerability, or dose accuracy.

FAQs About Hydrocortisone Excipient Commercialization

Can hydrocortisone be reformulated as a pediatric liquid?

Yes. A liquid can improve administration for children who cannot swallow tablets, but taste masking, chemical stability, microbial control, dosing accuracy, and preservative exposure are key constraints. Granules may offer better stability than an aqueous liquid.

Which excipient strategy is best for once-daily hydrocortisone?

A modified-release multiparticulate or capsule system is generally the most technically credible approach. The product must demonstrate controlled exposure, acceptable food-effect performance, and clinical relevance to cortisol replacement.

Are hydrocortisone topical products eligible for OTC commercialization?

Some low-strength topical hydrocortisone products are marketed under applicable OTC frameworks, while higher strengths, routes, or indications may require prescription approval. The regulatory status depends on strength, dosage form, indication, labeling, and jurisdiction.

Can a hydrocortisone formulation patent block all generic products?

No. A formulation patent generally covers only the claimed composition, process, use, or delivery system. A generic applicant may avoid the claims through a different excipient system or dosage form, subject to regulatory and patent requirements.

Which hydrocortisone product has the highest excipient-driven value?

Pediatric granules and modified-release oral products generally offer the strongest excipient-driven value because they address dose accuracy, administration, adherence, and pharmacokinetic limitations that conventional hydrocortisone tablets do not solve.

References

1. U.S. Food and Drug Administration. (2020). Alkindi Sprinkle prescribing information. FDA.
2. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. FDA.
3. European Medicines Agency. (2021). Efmody: EPAR product information. EMA.
4. U.S. Food and Drug Administration. (2023). Solu-Cortef prescribing information. FDA.
5. United States Pharmacopeia. (2024). General chapter <51>: Antimicrobial effectiveness testing. USP-NF.
6. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
7. International Council for Harmonisation. (2009). ICH Q8(R2): Pharmaceutical development. ICH.
8. International Council for Harmonisation. (2005). ICH Q9: Quality risk management. ICH.